Literature DB >> 25435145

2-Substituted Nγ-glutamylanilides as novel probes of ASCT2 with improved potency.

Michael L Schulte1, Eric S Dawson2, Sam A Saleh3, Madison L Cuthbertson4, H Charles Manning5.   

Abstract

Herein, we report the discovery and structure-activity relationships (SAR) of 2-substituted glutamylanilides as novel probes of the steric environment comprising the amino acid binding domain of alanine-serine-cysteine transporter subtype 2 (ASCT2). Focused library development led to three novel, highly potent ASCT2 inhibitors, with N-(2-(morpholinomethyl)phenyl)-L-glutamine exhibiting the greatest potency in a live-cell glutamine uptake assay. This level of potency represents a three-fold improvement over the most potent, previously reported inhibitor in this series, GPNA. Furthermore, this and other compounds in the series exhibit tractable chemical properties for further development as potential therapeutic leads.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ASCT2; Cancer; Glutamine; Metabolism; SLC1A5

Mesh:

Substances:

Year:  2014        PMID: 25435145      PMCID: PMC4372298          DOI: 10.1016/j.bmcl.2014.10.098

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

1.  Defining substrate and blocker activity of alanine-serine-cysteine transporter 2 (ASCT2) Ligands with Novel Serine Analogs.

Authors:  Thomas Albers; William Marsiglia; Taniya Thomas; Armanda Gameiro; Christof Grewer
Journal:  Mol Pharmacol       Date:  2011-11-23       Impact factor: 4.436

2.  Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways.

Authors:  Toshiaki Watanabe; Takashi Kobunai; Yoko Yamamoto; Keiji Matsuda; Soichiro Ishihara; Keijiro Nozawa; Hisae Iinuma; Hiroki Ikeuchi; Kiyoshi Eshima
Journal:  Eur J Cancer       Date:  2011-04-29       Impact factor: 9.162

3.  Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site.

Authors:  C Sean Esslinger; Kimberly A Cybulski; Joseph F Rhoderick
Journal:  Bioorg Med Chem       Date:  2005-02-15       Impact factor: 3.641

4.  Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells.

Authors:  Bryan C Fuchs; J Christian Perez; Julie E Suetterlin; Sofia B Chaudhry; Barrie P Bode
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-10-16       Impact factor: 4.052

5.  SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.

Authors:  Mohamed Hassanein; Megan D Hoeksema; Masakazu Shiota; Jun Qian; Bradford K Harris; Heidi Chen; Jonathan E Clark; William E Alborn; Rosana Eisenberg; Pierre P Massion
Journal:  Clin Cancer Res       Date:  2012-12-04       Impact factor: 12.531

Review 6.  MYC-induced cancer cell energy metabolism and therapeutic opportunities.

Authors:  Chi V Dang; Anne Le; Ping Gao
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

7.  In vitro Characterization of a small molecule inhibitor of the alanine serine cysteine transporter -1 (SLC7A10).

Authors:  Jeffrey M Brown; Lisa Hunihan; Margaret M Prack; David G Harden; Joanne Bronson; Carolyn D Dzierba; Robert G Gentles; Adam Hendricson; Rudy Krause; John E Macor; Ryan S Westphal
Journal:  J Neurochem       Date:  2013-12-10       Impact factor: 5.372

8.  Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma.

Authors:  Deborah Witte; Najeeba Ali; Nicole Carlson; Mamoun Younes
Journal:  Anticancer Res       Date:  2002 Sep-Oct       Impact factor: 2.480

9.  Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.

Authors:  Daniela Gaglio; Christian M Metallo; Paulo A Gameiro; Karsten Hiller; Lara Sala Danna; Chiara Balestrieri; Lilia Alberghina; Gregory Stephanopoulos; Ferdinando Chiaradonna
Journal:  Mol Syst Biol       Date:  2011-08-16       Impact factor: 11.429

10.  ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.

Authors:  K Shimizu; K Kaira; Y Tomizawa; N Sunaga; O Kawashima; N Oriuchi; H Tominaga; S Nagamori; Y Kanai; M Yamada; T Oyama; I Takeyoshi
Journal:  Br J Cancer       Date:  2014-03-06       Impact factor: 7.640

View more
  13 in total

1.  Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.

Authors:  Mohamed Hassanein; Matthew R Hight; Jason R Buck; Mohammed N Tantawy; Michael L Nickels; Megan D Hoeksema; Bradford K Harris; Kelli Boyd; Pierre P Massion; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

2.  2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport.

Authors:  Michael L Schulte; Alexandra B Khodadadi; Madison L Cuthbertson; Jarrod A Smith; H Charles Manning
Journal:  Bioorg Med Chem Lett       Date:  2015-12-11       Impact factor: 2.823

3.  Radiosynthesis, in vitro and preliminary in vivo evaluation of the novel glutamine derived PET tracers [18F]fluorophenylglutamine and [18F]fluorobiphenylglutamine.

Authors:  Tristan Baguet; Jeroen Verhoeven; Glenn Pauwelyn; Jiyun Hu; Patricia Lambe; Stef De Lombaerde; Sarah Piron; Sam Donche; Benedicte Descamps; Ingeborg Goethals; Christian Vanhove; Filip De Vos; M Hassan Beyzavi
Journal:  Nucl Med Biol       Date:  2020-04-03       Impact factor: 2.408

Review 4.  Advances and Challenges in Rational Drug Design for SLCs.

Authors:  Rachel-Ann A Garibsingh; Avner Schlessinger
Journal:  Trends Pharmacol Sci       Date:  2019-09-10       Impact factor: 14.819

5.  Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2.

Authors:  Kurnvir Singh; Rose Tanui; Armanda Gameiro; Gilad Eisenberg; Claire Colas; Avner Schlessinger; Christof Grewer
Journal:  Bioorg Med Chem Lett       Date:  2016-12-27       Impact factor: 2.823

Review 6.  Attacking the supply wagons to starve cancer cells to death.

Authors:  Elizabeth M Selwan; Brendan T Finicle; Seong M Kim; Aimee L Edinger
Journal:  FEBS Lett       Date:  2016-03-22       Impact factor: 4.124

7.  Structural characterisation reveals insights into substrate recognition by the glutamine transporter ASCT2/SLC1A5.

Authors:  Amanda J Scopelliti; Josep Font; Robert J Vandenberg; Olga Boudker; Renae M Ryan
Journal:  Nat Commun       Date:  2018-01-02       Impact factor: 14.919

8.  ASCT2 (SLC1A5)-Deficient Mice Have Normal B-Cell Development, Proliferation, and Antibody Production.

Authors:  Etienne Masle-Farquhar; Angelika Bröer; Mehmet Yabas; Anselm Enders; Stefan Bröer
Journal:  Front Immunol       Date:  2017-05-12       Impact factor: 7.561

9.  Engineering Tumour Cell-Binding Synthetic Polymers with Sensing Dense Transporters Associated with Aberrant Glutamine Metabolism.

Authors:  Naoki Yamada; Yuto Honda; Hiroyasu Takemoto; Takahiro Nomoto; Makoto Matsui; Keishiro Tomoda; Masamitsu Konno; Hideshi Ishii; Masaki Mori; Nobuhiro Nishiyama
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

Review 10.  Carbon-11 and Fluorine-18 Labeled Amino Acid Tracers for Positron Emission Tomography Imaging of Tumors.

Authors:  Aixia Sun; Xiang Liu; Ganghua Tang
Journal:  Front Chem       Date:  2018-01-15       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.